Clinical significance of cytochrome P450 genetic polymorphism – part II. Cytochrome P450 2C9

1. Goldstein, J. A.: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 2001; 52, 349–355.

2. Miners, J. O., Birkett, D. J.: Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 1998; 45, 525–538.

3. Kirchheiner, J., Tsahuridu, M., Jabrane, W., Roots, I., Brockmöller, J.: The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Personalized Med. 2004; 1, 63–84.

4. Schwarz, U. I.: Clinical relevance of genetic polymorphisms in the human CYP2C9. Eur. J. Clin. Invest. 2003; 33, 23–30.

5. García-Martín, E., Martínez, C., Ladero, J. M., Agúndez, J. A.: Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol. Diag. Ther. 2006; 10, 29–40.

6. Rettie, A. E., Jones, J. P.: Clinical and toxicological relevance of CYP2C9: Drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol. 2005; 45, 477–494.

7. Aithal, G. P., Day, C .P., Kesteven, P. J., Daly, A. K.: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353, 717–719.

8. Linder, M. W., Looney, S., Adams, J. E., Johnson, N., Antonino-Green, D., Lacefield, N., Bukaveckas, B. L., Valdes R.: Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J. Thromb. Thrombolysis. 2002; 14, 227–232.

9. Scordo, M. G., Pengo, V., Spina, E., Dahl, M. L., Gusella, M., Padrini, R.: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 2002; 72, 702–710.

10. Peyvandi, F., Spreafico, M., Siboni, S. M., Moia, M., Mannucci, P. M.: CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin. Pharmacol. Ther. 2004; 75, 198–203.

11. Higashi, M. K., Veenstra, D. L., Kondo, L. M, Wittkowsky, A. K., Srinouanprachanh, S. L., Farin, F. M., Rettie, A. E.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287, 1690–1698.

12. Sanderson, S., Emery, J., Higgins, J.: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 2005; 7, 97–104.

13. Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K., Kamali, F.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106, 2329–2333.

14. Caldwell, M. D., Berg, R. L., Zhang, K. Q., Glurich, I., Schmelzer, J. R., Yale, S. H., Vidaillet, H. J., Burmester, J. K.: Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res. 2006; 5, 8–16.

15. Wadelius M., Chen L. Y., Lindh J. D., Eriksson, N., Ghori, M. J., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., Deloukas, P.: The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009; 113, 784–792.

16. Ferder, N. S., Eby, C. S., Deych, E., Harris, J. K., Ridker, P. M. Milligan, P. E ., Goldhaber, S. Z., King, C. R., Giri, T., McLeod, H. L., Glynn, R. J., Gage, B. F.: Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J. Thromb. Haemost. 2010; 8, 95–100.

17. Roper, N., Storer, B., Bona, R., Fang, M.: Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J. Mol. Diagn. 2010; 12, 283–291.

18. van Schie, R. M., Wadelius, M. I., Kamali, F., Daly, A. K., Manolopoulos, V. G., de Boer, A., Verhoef, T. I., Kirchheiner, J., Haschke-Becher, E., Briz, M., Rosendaal, F. R., Redekop, W. K., Pirmohamed, M., Maitland van der Zee A. H.: Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009; 10, 1687–1695.

19. Shon, J. H., Yoon, Y. R., Kim, K. A., Lim, Y. C., Lee, K. J., Park, J. Y., Cha, I. J., Flockhart, D. A., Shin, J. G.: Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 2002; 12, 111–119.

20. Yin, O. Q., Tomlinson, B., Chow, M. S.: CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin. Pharmacol. Ther. 2005; 78, 370–377.

21. Kirchheiner, J., Brockmöller, J., Meineke, I., Bauer, S., Rohde, W., Meisel, C., Roots, I.: Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther. 2002; 71, 286–296.

22. Niemi, M., Cascorbi, I., Timm, R., Kroemer, H. K., Neuvonen, P. J., Kivistö, K. T.: Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin. Pharmacol. Ther. 2002; 72, 32–332.

23. Kirchheiner, J., Bauer, S., Meineke, I., Rohde, W., Prang, V., Meisel, C., Roots, I., Brockmöller, J.: Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in helathy volunteers. Pharmacogenetics 2002; 12, 101–109.

24. Kirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B., Brockmöller, J.: Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet. 2005; 44, 1209–1225.

25. Suzuki, K., Yanagawa, T., Shibasaki, T., Kaniwa, N., Hasegawa, R., Tohkin, M.: Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepirid in subjects with type 2 diabetes. Diabetes Res. Clin. Pract. 2006; 72, 148–154.

26. Becker, M. L., Visser, L. E., Trienekens, P. H., Hofman, A., van Schaik, R. H., Stricker, B. H.: Cytochrome P450 2C9*2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin. Pharmacol. Ther. 2008; 83, 288–292.

27. Holstein A., Plaschke A., Ptak M., Egberts, E. H., El-Din, J., Brockmöller, J., Kirchheiner, J.: Association between CYP2C9 slow mwtabolizer gynotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol. 2005; 60, 103–106.

28. Ragia, G., Petridis, I., Tavridou, A., Christakidis, D., Manolopoulous, V. G.: Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009; 10, 1781–1787.

29. Kirchheiner J., Meineke I., Müller G., Bauer, S., Rohde, W., Meisel, C., Roots, I., Brockmöller, J.: Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin. Pharmacokinet. 2004; 43, 267–278.

30. Yasar, U., Forslund-Bergengren, C., Tybring, G., Dorado, P., Llerena, A., Sjöqvist, F., Eliasson, E., Dahl, M. L.: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther. 2002; 71, 89–98.

31. Sekino, K., Kubota, T., Okada, Y., Yamada, Y., Yamamoto, K., Horiuchi, R., Kimura, K., Iga, T.: Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur. J. Clin. Pharmacol. 2003; 59, 589–592.

32. Lajer, M., Tarnow, S., Andersen, S., Parving, H. H.: CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy. Diabet. Med. 2007; 24, 322–328.

33. Joy, M. S., Dornbrook-Lavender, K., Blaisdell, J., Hilliard, T., Boyette, T., Hu, Y., Hogan, S. L., Candiani, C., Falk, R. J., Goldstein, J. A.: CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur. J. Clin. Pharmacol. 2009; 65, 947–953.

34. Lee, C. R., Pieper, J. A., Hinderliter, A. L., Blaisdell, J. A., Goldstein, J. A.: Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy 2003; 23, 720–725.

35. Donner, K. M., Hiltunen, T. P., Suonsyrjä, T., Hannila-Handelberg, T., Tikkanen, I., Antikainen, M., Hirvonen, A., Kontula, K.: CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men. J. Hypertens. 2009; 27, 2001–2009.

36. Chen, G., Jiang, S., Mao, G., Zhang, S., Hong, X., Tang, G., Li, Z., Liu, X., Zhang, Y., Xing, H., Wang, B., Yu, Y, Xu, X.: CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients. Methods. Find. Exp. Clin. Pharmacol. 2006; 28, 19–24.

37. Hallberg, P., Karlsson, J., Kurland, L., Lind, L., Kahan, T., Malmqvist, K., Ohman, K. P., Nyström, F., Melhus, H.: The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J. Hypertens. 2002; 20, 2089–2093.

38. Hong, X., Zhang, S., Mao, G., Jiang, S., Zhang, Y., Yu, Y., Tang, G., Xing, H., Xu, X.: CYP2C9*3 allelic variant is associated with netabolism of irbesartan in Chinese population. Eur. J. Clin. Pharmacol. 2005; 61, 627–634.

39. Blanco, G., Martínez, C., García-Martín, E., Agúndez, J. A.: Cytochrome P450 gene polymorphisms and variability in response to NSAIDS. Clin. Res. Reg. Affairs 2005; 22, 57–81.

40. Kirchheiner, J., Störmer, E., Meisel, C., Steinbach, N., Roots, I., Brockmöller, J.: Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003; 13, 473–480.

41. Lundblad, M. S., Ohlsson, S., Johansson, P., Lafolie, P., Eliasson, E.: Accumulation of celekoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3. Clin. Pharmacol. Ther. 2006; 79, 287–288.

42. López-Rodríguez, R., Novalbos, J., Gallego-Sandín, S., Román-Martínez, M., Torrado, J., Gisbert, J. P., Abad-Santos, F.: Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol. Res. 2008; 58, 77–84.

43. García-Martín, E., Martínez, C., Tabarés, B., Frías, J., Agúndez, J. A.: Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther. 2004; 76, 119–127.

44. Kirchheiner, J., Meineke, I., Freytag, G., Meisel, C., Roots, I., Brockmöller, J.: Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenase 1 and 2. Clin. Pharmacol. Ther. 2002; 72, 62–75.

45. Samowitz, W. S., Wolff, R. K., Curtin, K., Sweeney, C., Ma, K. N., Andersen, K., Levin, T. R., Slattery, M. L.: Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal prevention. Clin. Gastroenterol. Hepatol. 2006; 4, 894–901.

46. Zhang, Y., Zhong, D., Si, D., Guo, Y., Chen, X., Zhou, H.: Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br. J. Clin. Pharmacol. 2005; 59, 14–17.

47. Vianna-Jorge, R., Perini, J. A., Rondinelli, E., Suarez-Kurtz, G.: CYP2C9 genotypes and pharmacokinetics of tenoxicam in Brazilians. Clin. Pharmacol. Ther. 2004; 76, 18–26.

48. Perini, J. A., Vianna-Jorge, R., Brogliato, A. R., Suarez-Kurtz, G.: Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin. Pharmacol. Ther. 2005; 78, 362–369.

49. Shimamoto, J., Ieiri, I., Urae, A., Kimura, M., Irie, S., Kubota, T., Chiba, K., Ishizaki, T., Otsubo, K., Higuchi, S.: Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur. J. Clin. Pharmacol. 2000; 56, 65–68.

50. Yasar, Ü., Eliasson, E., Forslund-Bergengren, C., Tybring, G., Gadd, M., Sjöqvist, F., Dahl, M. L.: The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur. J. Clin. Pharmacol. 2001; 57, 729–735.

51. Martin, J. H., Begg, E. J., Kennedy, M. A., Roberts, R., Barclay, M. L.: Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br. J. Clin. Pharmacol. 2001; 51, 627–630.

52. Martínez, C., Blanco, G., Ladero, J. M., García-Martín, E., Taxonera, C., Gamito, F. G., Diaz-Rubio, M., Agúndez, J. A.: Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br. J. Pharmacol. 2004; 141, 205–208.

53. Scarcelli, C., Colaizzo, D., Grandone, E., Nir,o V., Andriulli, A., Leandro, G., Di Mario, F., Dallapiccola, B.: Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastronenterology 2007; 133, 465–471.

54. Carbonell, N., Verstuyft, C., Massard, J., Letierce, A., Cellier, C., Deforges, L., Saliba, F., Delchier, J. C., Becquemont, L.: CYP2C9*3 loss-of-function allele is associated with acute upper gastrointestinal bleeding related to the use of NSAIDs other than aspirin. Clin. Pharmacol. Ther. 2010; 87, 693–698.

55. Tassaneeyakul, W., Veronese, M. E., Birkett, D. J., Doecke, C. J., McManus, M. E., Sansom, L. N., Miners, J. O.: Co-regulation of phenytoin and tolbutamide metabolism in humans. Br. J. Clin. Pharmac. 1992; 34, 494–498.

56. Taguchi, M., Hongou, K., Yagi, S., Miyawaki, T., Takizawa, M., Aiba, T., Hashimoto, Y.: Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients. Drug. Metab. Pharmacokinet. 2005; 20, 107–112.

57. Kerb, R., Aynacioglu, A. S., Brockmöller, J., Schlagenhaufer, R., Bauer, S., Szekeres, T., Hamwi, A., Fritzer-Szekeres, M., Baumgartner, C., Ongen, H. Z., Güzelbey, P., Roots, I., Brinkmann, U.: The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics 2001; 1, 204–210.

58. Lee, S. Y., Lee, S. T., Kim, J. W.: Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J. Biochem. Mol. Biol. 2007; 40, 448–452.

59. Aynacioglu, A. S., Brockmöller, J., Bauer, S., Sachse, C., Güzelbey, P., Ongen, Z., Nacak, M., Roots, I.: Frequency of cytochrome P4502C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 1999; 48: 409–415.

60. Tate, S. K., Depondt, C., Sisodiya, S. M., Cavalleri, G. L., Schorge, S., Soranzo, N., Thom, M., Sen, A., Shorvon, S. D., Sander, J. W., Wood, N. W., Goldstein, D. B.: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl. Acad. Sci. 2005; 102, 5507–5512.

61. van der Weide, J., Steijns, L. S., van Weelden, M. J., de Haan, K.: The effect of genetic polymorphisms of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; 11, 287–291.

62. Kesavan, R., Narayan, S. K., Adithan, C.: Influence of CYP2C9 and Cyp2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur. J. Clin. Pharmacol. 2010; 66, 689–696.

63. Ninomiya, H., Mamiya, K., Matsuo, S., Leiri, I., Higuchi, S., Tashiro, N.: Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther. Drug. Monit. 2000; 22, 230–232.

64. Kidd, R. S., Curry, T. B., Gallagher, S., Edeki, T., Blaisdell, J., Goldstein, J. A.: Identification of a null allele of CYP2C9 in an African-american exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11, 803–808.

65. Brandolese, R., Scordo, M. G., Spina, E., Gusella, M., Padrini, R.: Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin. Pharmacol. Ther. 2001; 70, 391–394.

66. McCluggage, L. K., Voils, S. A., Bullock, M. R.: Phenytoin toxicity due to genetic polymorphism. Neurocrit. Care 2009; 10, 222–224.

67. Soga, Y., Nishimura, F., Ohtsuka, Y., Araki, H., Iwamoto, Y., Naruishi, H., Shiomi, N., Kobayashi, Y., Takashiba, S., Shimizu, K., Gomita, Y., Oka, E.: CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci. 2004; 74, 827–834.

68. Lee, A. Y., Kim, M. J., Chey, W. Y., Choi, J., Kim, B. G.: Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur. J. Clin. Pharmacol. 2004; 60, 155–159.

69. P450 Drug Interaction Table. http://medicine.iupui.edu/ clinpharm/ddis/table.aspx (17. 5. 2011).

70. Suchopár, J., Buršík, J., Mach, R., Prokeš, M.: Kompendium lékových interakcí. 1. vyd. InfoPharm 2005.

71. Baxter, K., Davis, M., Driver, S. (eds.): Stockley’s drug interactions, 8th ed. Suffolk: Pharmaceuticals Press, 2008.